Acasti Pharma, Inc. - (ACST) News
Filter ACST News Items
ACST News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
ACST News Highlights
- ACST's 30 day story count now stands at 2.
- Over the past 12 days, the trend for ACST's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
- DEC, GTX and RARE are the most mentioned tickers in articles about ACST.
Latest ACST News From Around the Web
Below are the latest news stories about ACASTI PHARMA INC that investors may wish to consider to help them evaluate ACST as an investment opportunity.
Will Acasti Pharma (NASDAQ:ACST) Spend Its Cash Wisely?Just because a business does not make any money, does not mean that the stock will go down. For example, although... |
Acasti to Participate in Upcoming San Francisco Investor Conferences in January 2024PRINCETON, N.J., Dec. 13, 2023 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (Nasdaq: ACST) (Acasti or the Company), a late-stage, biopharma company advancing GTX-104, its novel intravenous formulation of nimodipine being developed to address the high unmet medical needs for a rare disease, aneurysmal Subarachnoid Hemorrhage (aSAH), today announced that Chief Executive Officer Prashant Kohli will participate in the following investor and industry networking events in San Francisco, California during th |
Acasti Announces Second Quarter 2024 Financial Results and Business HighlightsAnnounced Dosing of First Patient in Pivotal STRIVE-ON Phase 3 Randomized Trial for GTX-104 Completed $7.5 Million Private Placement Equity Financing led by ADAR1 Partners, LP, Providing Funding Well Beyond Anticipated Submission of GTX-104 New Drug Application (NDA) Highlighted the Potential of GTX-104 as New Treatment Standard for Aneurysmal Subarachnoid Hemorrhage (aSAH) in Key Opinion Leader Virtual WebinarPresented Poster on Pharmacokinetic Comparison of GTX-104 with Oral Nimodipine at 2023 |
Acasti Announces Dosing of First Patient in GTX-104 STRIVE-ON TrialWith achievement of enrollment milestone, pivotal STRIVE-ON safety trial on track for potential NDA submission anticipated to occur in the first half of calendar 2025 Recently announced $7.5 million private placement financing extends projected cash runway to the first calendar quarter of 2026 PRINCETON, N.J., Oct. 23, 2023 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (Nasdaq: ACST) (Acasti or the Company), a late-stage, biopharma company advancing GTX-104, its novel formulation of nimodipine that add |
Acasti Pharma to Host KOL Event on GTX-104: A Potential New Treatment Standard for Rare and Life-Threatening aneurysmal Subarachnoid Hemorrhage (aSAH)Virtual Webinar to Take Place October 11, 2023 at 2:00pm ETPRINCETON, N.J., Oct. 04, 2023 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (Nasdaq: ACST) (Acasti or the Company), a late-stage, biopharma company advancing GTX-104, its novel formulation of nimodipine that addresses the high unmet medical needs for a rare disease, aneurysmal subarachnoid hemorrhage (aSAH), today announced that it will host a virtual KOL event titled GTX-104: a potential new treatment standard for rare and life-threatening aS |
Acasti Announces $7.5 Million Private Placement Equity FinancingPRINCETON, N.J., Sept. 26, 2023 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (Nasdaq: ACST) (Acasti or the Company), a late-stage, biopharma company advancing GTX-104, its novel formulation of nimodipine that addresses the high unmet medical needs for a rare disease, aneurysmal subarachnoid hemorrhage (aSAH), today announced that it has closed a private placement of the Company's securities pursuant to the terms of a securities purchase agreement, dated September 24, 2023, by and between the Company a |
Acasti to Participate in the H.C. Wainwright Global Investment ConferencePRINCETON, N.J., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (Nasdaq: ACST) (Acasti or the Company), a late-stage, biopharma company advancing GTX-104, its novel formulation of nimodipine that addresses the high unmet medical needs for a rare disease, aneurysmal subarachnoid hemorrhage (aSAH), today announced that the Company’s management will be participating in the 25th Annual H.C. Wainwright Global Investment Conference, to be held September 11-13 , 2023 in New York, NY. Prashant Ko |
TEVA to Pay $225 Million to Settle Price-Fixing Charges (Revised)TEVA agrees to pay a fine of $225 million over five years per a DPA. Out of this amount, $22.5 million will be due each year from 2024 through 2027 and $135 million will become due in 2028. |
TEVA to Pay $250 Million to Settle Price-Fixing ChargesTEVA agrees to pay a fine of $225 million over five years per a DPA. Out of this amount, $22.5 million will be due each year from 2024 through 2027 and $135 million will become due in 2028. |
Acasti Announces First Quarter 2024 Financial Results and Business HighlightsNew leadership team singularly focused on executing GTX-104 strategyAnnounced alignment with the U.S. Food and Drug Administration (FDA) for Pivotal STRIVE-ON Phase 3 Safety Trial for GTX-104 with first patient expected to be dosed prior to the end of 2023Cash and cash equivalents as of quarter end were $21.6 million; company reiterates projected cash runway to Q2 2025, beyond potential submission of GTX-104 New Drug Application (NDA)Abstract of pharmacokinetic comparison of GTX-104 with oral ni |